We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+22.23%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$2.09B
AUM Growth
+$551M
Cap. Flow
+$510M
Cap. Flow %
24.34%
Top 10 Hldgs %
59.78%
Holding
66
New
16
Increased
22
Reduced
7
Closed
10

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$61.8M
2
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$50.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$44.8M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$42.8M
5
DERM
Dermira, Inc.
DERM
+$41.5M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$56.8M
2
BMY icon
Bristol-Myers Squibb
BMY
+$28M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$16.8M
4
CASC
Cascadian Therapeutics, Inc.
CASC
+$9.2M
5
AGEN
Agenus
AGEN
+$7.85M

Sector Composition

Rank Sector Weight
1 Healthcare 83.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$247M 11.82%
16,939,461
+875,000
+5% +$14.3M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$143M 6.83%
9,505,447
+2,242,325
+31% +$34.1M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$11.9B
$139M 6.62%
1,710,995
+521,471
+44% +$44.8M
IOVA icon
4
Iovance Biotherapeutics
IOVA
$2.03B
$137M 6.52%
8,078,505
+2,825,055
+54% +$42.8M
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$135M 6.45%
4,398,101
– –
ASND icon
6
Ascendis Pharma A/S
ASND
$16.6B
$135M 6.44%
2,063,336
+382,312
+23% +$21.5M
GBT
7
DELISTED
Global Blood Therapeutics, Inc.
GBT
$85.3M 4.07%
1,765,548
-76,348
-4% -$4.26M
AVXS
8
DELISTED
AveXis, Inc. Common Stock
AVXS
$83.4M 3.99%
675,262
+79,045
+13% +$9.39M
TGTX icon
9
TG Therapeutics
TGTX
$8.16B
$74.3M 3.55%
5,229,619
+1,935,156
+59% +$24.7M
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$73.3M 3.5%
5,158,683
+722,500
+16% +$10.7M
ARGX icon
11
argenx
ARGX
$54.9B
$69.4M 3.32%
863,275
+58,400
+7% +$4.41M
CLVS
12
DELISTED
Clovis Oncology, Inc.
CLVS
$61.6M 2.94%
1,165,884
+63,000
+6% +$3.68M
PBYI icon
13
Puma Biotechnology
PBYI
$397M
$56.2M 2.68%
+825,368
New +$61.8M
MDCO
14
DELISTED
Medicines Co
MDCO
$53.9M 2.57%
1,635,817
+339,257
+26% +$10.6M
ASMB icon
15
Assembly Biosciences
ASMB
$494M
$53.8M 2.57%
91,161
+2,116
+2% +$1.31M
PCRX icon
16
Pacira BioSciences
PCRX
$1.04B
$53.4M 2.55%
1,715,072
+866,500
+102% +$30.9M
ECYT
17
DELISTED
Endocyte, Inc. Common Stock
ECYT
$51.8M 2.47%
+5,695,200
New +$31.4M
ZGNX
18
DELISTED
Zogenix, Inc.
ZGNX
$47.6M 2.27%
1,189,213
-74,100
-6% -$2.94M
VNDA icon
19
Vanda Pharmaceuticals
VNDA
$301M
$46.8M 2.23%
2,775,191
+1,366,245
+97% +$22.9M
ARMO
20
DELISTED
ARMO BioSciences, Inc. Common Stock
ARMO
$45.2M 2.16%
+1,207,500
New +$50.8M
DVAX
21
DELISTED
Dynavax Technologies
DVAX
$32.8M 1.56%
+1,650,700
New +$28.5M
ARRY
22
DELISTED
Array Biopharma Inc
ARRY
$31.4M 1.5%
1,922,655
-3,545,374
-65% -$56.8M
DERM
23
DELISTED
Dermira, Inc.
DERM
$27.4M 1.31%
3,427,378
+1,907,378
+125% +$41.5M
GYRE icon
24
Gyre Therapeutics
GYRE
$630M
$26.4M 1.26%
136,550
+83,217
+156% +$15.5M
AZN icon
25
AstraZeneca
AZN
$269B
$26.2M 1.25%
375,150
– –
1
2 3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q1 2018 Portfolio in Review

As of Q1 2018, Avoro Capital Advisors held 66 positions worth $2.09B, up 36% from $1.54B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Avoro Capital Advisors deployed $510M of net new capital in Q1 2018, opening 16 new positions and adding to 22 existing holdings. Its largest new stake was Puma Biotechnology: 825,368 shares worth $56.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 77% a quarter earlier.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $56.8M trimmed.

  • Avoro Capital Advisors's largest Q1 2018 buy was Puma Biotechnology: 825,368 shares worth $56.2M.
  • Avoro Capital Advisors added most to BioMarin Pharmaceuticals in Q1 2018, an estimated $44.8M increase.
  • Avoro Capital Advisors's biggest Q1 2018 reduction was Array Biopharma Inc, cutting an estimated $56.8M.
  • Avoro Capital Advisors fully exited Bristol-Myers Squibb in Q1 2018, selling an estimated $28M.
  • Avoro Capital Advisors's ten largest holdings make up 60% of its $2.09B portfolio in Q1 2018.
  • Avoro Capital Advisors opened 16 new positions and closed 10 in Q1 2018.
  • Avoro Capital Advisors's portfolio value rose 36% quarter-over-quarter to $2.09B.

Based on Avoro Capital Advisors's 13F filing for Q1 2018, filed 15 May 2018.